- Home
- SRTA vs RIGL Comparison
SRTA vs RIGL Comparison
Compare SRTA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRTA | RIGL |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | 601 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.4M | 564.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | SRTA | RIGL |
|---|---|---|
| Price | $5.79 | $40.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $7.81 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 1.1M | 310.6K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $39.27 | N/A |
| Revenue Next Year | $8.52 | $12.75 |
| P/E Ratio | ★ $9.88 | $29.71 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $3.85 | $24.84 |
| 52 Week High | $6.50 | $52.24 |
Technical Indicators
Market Signals| Indicator | SRTA | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 53.79 |
| Support Level | $4.91 | $33.93 |
| Resistance Level | $5.89 | $44.42 |
| Average True Range (ATR) | 0.27 | 1.96 |
| MACD | 0.09 | -0.16 |
| Stochastic Oscillator | 65.63 | 49.67 |
Price Performance
Historical ComparisonAbout SRTA Strata Critical Medical Inc.
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.